Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium picosulfate + magnesium oxide + citric acid is a low-volume, dual-action bowel preparation kit indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients. The product contains sodium picosulfate, a prodrug that is hydrolyzed by colonic bacteria to form the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which directly stimulates the colonic mucosa to increase peristalsis. The other components, magnesium oxide and anhydrous citric acid, react in water to form magnesium citrate, an osmotic laxative that promotes water retention in the intestinal lumen. This combination effectively clears the bowel with a lower fluid volume requirement compared to traditional polyethylene glycol (PEG) solutions, often leading to improved patient compliance and tolerability. It is marketed under various brand names including Clenpiq (a ready-to-drink formulation) and Prepopik.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium picosulfate + magnesium oxide + citric acid.